CSL's share price has plunged to a six-year low after it downgraded its growth forecasts amid falling US vaccination rates and reduced demand for China given government cost-control measures.
The blood product giant's shares around midday on Tuesday had dropped 15.9 per cent to $177.17, its lowest level since 2018, after CSL cut its guidance for revenue growth to two to three per cent, from four to five per cent. It also trimmed its profit forecast to four to seven per cent growth, from seven to 10 per cent previously.
